SCHEMBL17420206

SCHEMBL17420206

CC(=O)c1cc2cc(NC(=O)c3cc(NC(=O)c4ccc(CN5CCC(N(C)C)C5)c(C(F)(F)F)c4)ccc3C)cnc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 11/20 0.59
▸ BCR P11274 8/20 0.59
▸ BRAF P15056 4/20 0.57
▸ LYN P07948 3/20 0.57
▸ CSK P41240 2/20 0.57
▸ MAPK14 Q16539 2/20 0.57
▸ RIPK2 O43353 1/20 0.57
▸ LCK P06239 1/20 0.57
▸ FYN P06241 1/20 0.57
▸ RET P07949 1/20 0.57
▸ PDGFRB P09619 1/20 0.57
▸ ARAF P10398 1/20 0.57
▸ NQO2 P16083 1/20 0.57
▸ EPHA2 P29317 1/20 0.57
▸ EPHB2 P29323 1/20 0.57
▸ ABL2 P42684 1/20 0.57
▸ FRK P42685 1/20 0.57
▸ MAPKAPK2 P49137 1/20 0.57
▸ IRAK1 P51617 1/20 0.57
▸ EPHB3 P54753 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17426694 1.00 ABL1 (0.59) ABL1BCRBRAFLYNCSK
SCHEMBL3814061 0.94 CSK (0.59) ABL1BCRBRAFLYNCSK
SCHEMBL15859845 0.92 CSK (0.58) ABL1BCRBRAFLYNCSK
SCHEMBL17420203 0.92 CSK (0.58) ABL1BCRBRAFLYNCSK
SCHEMBL15859876 0.92 CSK (0.58) ABL1BCRBRAFLYNCSK
SCHEMBL16603010 0.89 CSK (0.59) ABL1BCRBRAFLYNCSK
SCHEMBL17313603 0.89 ABL1 (0.57) ABL1BCRBRAFLYNCSK
SCHEMBL15860133 0.89 ABL1 (0.57) ABL1BCRBRAFLYNCSK
SCHEMBL15860135 0.89 ABL1 (0.57) ABL1BCRBRAFLYNCSK
SCHEMBL15859840 0.88 BRAF (0.61) ABL1BCRBRAFEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9403823-B2 Protein kinase inhibitors ORIBASE PHARMA (FR) 2016-08-02 — — US disclosed
US-20160009709-A1 PROTEIN KINASE INHIBITORS ORIBASE PHARMA (FR) 2016-01-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009709-A1 PROTEIN KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K2 ABL1 128/4885BCR 1053/4885BRAF 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback